Key Issues
- Evidence of a constructed fraud shell: Anbio’s structure, addresses, products, and filings consistently fail basic verification.
- Market manipulation indicators: Share inflation, fake investors, and dramatic stock swings point to an orchestrated pump-and-dump cycle.
- Regulatory noncompliance risks: Misleading disclosures, nonexistent operations, and false corporate information signal potential SEC and Nasdaq violations.
Investor Takeaways
- Anbio lacks real business substance—no facilities, no supply chain, and likely fabricated products.
- Insider-controlled structure and suspicious investors suggest the IPO enriched a small circle at public expense.
- Extreme price volatility is engineered, not market-driven, making the stock highly dangerous for retail investors.
We also recommend this insightful Reddit thread: Anbio Biotechnology – A Very Mysterious Company.
